Advertisement

Nicotinic Attention-Deficit/Hyperactivity Disorder Treatment

  • Edward D. Levin
    Correspondence
    Address correspondence to Edward D. Levin, Ph.D., Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Triangle Biotechnology Center, Neurobehavioral Research Laboratory, DUMC Box 104790, 323 Foster St, Durham, NC 27710
    Affiliations
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina
    Search for articles by this author
      Nicotine is not native to the human nervous system, but nicotinic receptors certainly are. Nicotine is the prototypic agonist for one of the two principal subtypes of acetylcholine receptors. Nicotinic receptors are critical for a wide variety of neurobehavioral functions, including muscle movement (with actions in the neuromuscular junction), sympathetic and parasympathetic responsivity (with actions in the autonomic ganglia), cognitive function (with actions in the hippocampus and frontal cortex), emotional function (with actions in the amygdala), and reward (with actions in the ventral tegmental area). Nicotine is notorious as the primary (but not only) psychoactive chemical in tobacco. Nicotine self-administration is an essential component of tobacco addiction. However, like other drugs with abuse liability, such as opiates and benzodiazepines, nicotinic drugs may have useful therapeutic applications. The article by Potter et al. (
      • Potter A.S.
      • Dunbar G.
      • Mazzulla E.
      • Hosford D.
      • Newhouse P.A.
      AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
      ) in this issue describes the efficacy of a novel nicotinic agonist AZD3480 in reducing an array of cognitive and emotional symptoms of attention-deficit/hyperactivity disorder (ADHD).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Potter A.S.
        • Dunbar G.
        • Mazzulla E.
        • Hosford D.
        • Newhouse P.A.
        AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
        Biol Psychiatry. 2014; 75: 207-214
        • Newhouse P.
        • Singh A.
        • Potter A.
        Nicotine and nicotinic receptor involvement in neuropsychiatric disorders.
        Curr Top Med Chem. 2004; 4: 267-282
        • Levin E.D.
        • Conners C.K.
        • Silva D.
        • Canu W.
        • March J.
        Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.
        Exp Clin Psychopharmacol. 2001; 9: 83-90
        • Levin E.D.
        • Conners C.K.
        • Sparrow E.
        • Hinton S.C.
        • Erhardt D.
        • Meck W.H.
        • et al.
        Nicotine effects on adults with attention-deficit/hyperactivity disorder.
        Psychopharmacology (Berl). 1996; 123: 55-63
        • Potter A.S.
        • Newhouse P.A.
        Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.
        Psychopharmacology (Berl). 2004; 176: 182-194
        • Shytle R.D.
        • Silver A.A.
        • Wilkinson B.J.
        • Sanberg P.R.
        A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder.
        World J Biol Psychiatry. 2002; 3: 150-155
        • Hahn B.
        • Sharples C.G.
        • Wonnacott S.
        • Shoaib M.
        • Stolerman I.P.
        Attentional effects of nicotinic agonists in rats.
        Neuropharmacology. 2003; 44: 1054-1067
        • Rezvani A.H.
        • Kholdebarin E.
        • Brucato F.H.
        • Callahan P.M.
        • Lowe D.A.
        • Levin E.D.
        Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.
        Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 269-275
        • Sydserff S.
        • Sutton E.J.
        • Song D.
        • Quirk M.C.
        • Maciag C.
        • Li C.
        • et al.
        Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.
        Biochem Pharmacol. 2009; 78: 880-888
        • Wilens T.E.
        • Biederman J.
        • Spencer T.J.
        • Bostic J.
        • Prince J.
        • Monuteaux M.C.
        • et al.
        A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder.
        Am J Psychiatry. 1999; 156: 1931-1937